Topic: hypoxia/ischemia

The aim of this study was to address the urgent global need for an effective therapeutic strategy against acute stroke and perinatal asphyxia. A promising answer to limitations of currently existing therapies might be the newly designed Pathway Preferential Estrogen-1 (PaPE-1). Estrogen receptor-mediated signaling is pivotal for neuroprotection, and its impairment during hypoxia/ischemia may increase the risk of cerebral infarction. Our goal was to selectively activate non-nuclear estrogen receptors signaling, providing a wide therapeutic window and minimizing adverse hormonal effects associat

We have developed a novel way to block TRPM4 channel by applying specific antibodies that bind to an extracellular region close to the channel pore. The TRPM4 antibodies include a polyclonal antibody M4P that is specific to rodent TRPM4, a monoclonal antibody M4M that is specific to human TRPM4, and most recently, a humanized antibody M4H modified from M4M.The inhibitory effect of TRPM4 antibodies is achieved via two pathways: 1) directly blocking channel activity; 2) downregulating the surface expression of TRPM4. Under disease condition such as hypoxia/ischemia, blocking TRPM4 activity by ou